Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

Table 4

Characteristics of patients with CMV infections and timing of CMV infections in relation to transplantation and the universal prophylaxis protocol.

Group CMV D/R	Patients with CMV infection	Days from transplant till first event (mean ± SD)	Days from the end of the universal prophylaxis to first event, mean ± SD
Standard induction and maintenance therapy	22	958.1 ± 1215.9^a	817.1 ± 1223.8^b
D+/R−	7	508.4 ± 983.9	325.9 ± 983.9
R+	15	1167.9 ± 1286.3	1046.3 ± 1286.3
Extended alemtuzumab exposure	51^c	505.2 ± 548.9^a	140.2 ± 548.9^b
D+/R−	25	552.0 ± 661.7	187.0 ± 661.7
R+	25	474.1 ± 424.3	109.1 ± 424.3

Patients in the standard induction and maintenance therapy group received valganciclovir for 6 months if the CMV serostatus was D+/R−, and for 3 months if R+ or D−/R−. All patients in the extended alemtuzumab exposure group received valganciclovir for 12 months following transplantation. D/R: donor/recipient CMV serostatus; SD: standard deviation. ^aComparing these two values, . ^bComparing these two values, . ^cThere was one D−/R− transplant recipient in the extended alemtuzumab exposure group.